← Eichor
Study identifier: NCT06475651 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Characterization and Contribution of Genome-wide DNA Methylation (DNA Methylation Episignatures) in Rare Diseases With Prenatal Onset

Condition: Rare Fetal Genetic Diseases · Congenital Malformation  ·  Sponsor: Assistance Publique - Hôpitaux de Paris

PhaseN/A
Planned participants63
Who can joinAll sexes, 0 Years to 18 Years
Healthy volunteersYes

About this study

It is necessary to define reference DNA Methylation Episignatures from fetal DNA. The hypotheses are: * It is possible to define reference DNA Methylation Episignatures from fetal DNA extracted from amniotic fluid or frozen tissues collected during the postmortem examination * Fetal DNA Methylation Episignatures may be different to postanal DNA Methylation Episignatures defined on DNA extracted from blood

This description comes directly from the study's public registry record.

Talk to the study team

Nicolas BOURGON, MD, PhD  ·  +33 1 42 19 27 96  ·  nicolas.bourgon@aphp.fr

Nelly BRIAND, PhD  ·  0144381862  ·  nelly.briand@aphp.fr

Always discuss trial participation with your own doctor first.

Locations (1)

Department of Genomic Medicine for Rare Diseases and the Multidisciplinary Center for Prenatal Diagnosis of the Necker-Enfants malades HospitalParis, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06475651